NVO241101P139000
- 12.78
- 0.000.00%
Novo-Nordisk A/S Newsroom
Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
Express News | The afternoon session of the second day of medical insurance negotiations has started! Dezh, novo-nordisk a/s and others have entered.
Eli Lilly and Co (LLY.US) weight loss drug Mounjaro has been approved in Hong Kong and will be available for sale as early as the end of this year.
eli lilly and co is expected to start selling its popular weight loss drug in Hong Kong as early as the end of this year.
Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ
US stocks closed | The three major indices rose and fell unevenly, with Tesla soaring 22%, marking the largest increase in eleven years.
Economic data supports the market's bet on a routine 25 basis point rate cut by the Federal Reserve in November. The US stock market only saw a drop in the Dow, the first four-day consecutive decline since June, dragged down by IBM and Boeing. The Chinese concept index fell by 1.6% before halving its decline, while Li Auto Inc surged more than 1%.
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Study Finds High Costs, Few Benefits Associated With GLP-1 Weight Loss Drugs
Viking Therapeutics Jumps as Obesity Updates Outshine Q3 Beat
European Equities Traded in the US as American Depositary Receipts Rise Slightly Higher in Thursday Trading
Express News | Eli Lilly and Co will launch the obesity drug Mounjaro in Denmark next week.
Ozempic May Reduce the Risk of Alzheimer's. That's Huge for Novo Nordisk. -- Barrons.com
Express News | Research has found that novo-nordisk a/s weight loss drug Ozempic may help reduce the risk of Alzheimer's disease in the elderly.
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs
Novo Nordisk's Ozempic Linked to Reduced Risk of Alzheimer's Diagnoses, Study Says
Novo-Nordisk a/s (NVO.US) pressures the FDA in the usa to restrict semaglutide generics and requests them to be added to the list of substances with synthetic challenges.
novonordisk a/s (NVO.US) has requested the FDA to list semaglutide as a synthetic difficulty-verified substance.
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
Novo Nordisk to Present New Cardiometabolic and Renal Data, Including With Semaglutide, at Kidney Week 2024, ObesityWeek, The Liver Meeting, and AHA Scientific Sessions 2024
Market Chatter: Catalent-Novo Holdings Deal Opposed by Roche CEO